Financhill
Sell
25

ARDX Quote, Financials, Valuation and Earnings

Last price:
$5.32
Seasonality move :
-14.07%
Day range:
$5.18 - $5.43
52-week range:
$4.32 - $9.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.75x
P/B ratio:
7.32x
Volume:
3.4M
Avg. volume:
3.4M
1-year change:
-32.14%
Market cap:
$1.3B
Revenue:
$333.6M
EPS (TTM):
-$0.16

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARDX
Ardelyx
$111.2M -$0.00 72.66% -33.34% $10.75
BBIO
BridgeBio Pharma
$4M -$1.09 -78.03% -330% $53.50
ESPR
Esperion Therapeutics
$61.6M -$0.16 -60.09% -68.5% $6.63
INSM
Insmed
$102.4M -$1.16 19.4% -27.03% $95.54
RGEN
Repligen
$167.6M $0.41 6.71% 483.23% $194.07
UTHR
United Therapeutics
$734.7M $6.84 7.61% 6.87% $397.54
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARDX
Ardelyx
$5.32 $10.75 $1.3B -- $0.00 0% 3.75x
BBIO
BridgeBio Pharma
$32.19 $53.50 $6.1B -- $0.00 0% 26.99x
ESPR
Esperion Therapeutics
$1.58 $6.63 $312.6M -- $0.00 0% 0.91x
INSM
Insmed
$76.99 $95.54 $13.9B -- $0.00 0% 34.72x
RGEN
Repligen
$144.34 $194.07 $8.1B 633.44x $0.00 0% 12.80x
UTHR
United Therapeutics
$314.12 $397.54 $14.1B 12.77x $0.00 0% 5.30x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARDX
Ardelyx
46.54% 1.635 12.5% 3.95x
BBIO
BridgeBio Pharma
679.11% 1.994 32.94% 4.44x
ESPR
Esperion Therapeutics
-303.11% 3.463 67.84% 0.91x
INSM
Insmed
79.45% 6.110 8.91% 4.99x
RGEN
Repligen
21.04% 0.912 6.51% 7.03x
UTHR
United Therapeutics
4.45% 1.276 1.9% 4.80x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARDX
Ardelyx
$97.9M $8.1M -15.08% -24.57% 9.07% $9.2M
BBIO
BridgeBio Pharma
$3.8M -$221.3M -108.74% -- -4019.3% -$198.6M
ESPR
Esperion Therapeutics
$43.5M -$4.4M -- -- -7.08% -$35M
INSM
Insmed
$78.3M -$245.2M -82.19% -41989.34% -205.36% -$202.8M
RGEN
Repligen
$38.8M -$33.3M -1% -1.29% -19.78% $29.2M
UTHR
United Therapeutics
$660M $363.7M 18.64% 20.21% 54.95% $254.5M

Ardelyx vs. Competitors

  • Which has Higher Returns ARDX or BBIO?

    BridgeBio Pharma has a net margin of 4% compared to Ardelyx's net margin of -4506.12%. Ardelyx's return on equity of -24.57% beat BridgeBio Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    BBIO
    BridgeBio Pharma
    64.57% -$1.40 $263.8M
  • What do Analysts Say About ARDX or BBIO?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 102.07%. On the other hand BridgeBio Pharma has an analysts' consensus of $53.50 which suggests that it could grow by 66.2%. Given that Ardelyx has higher upside potential than BridgeBio Pharma, analysts believe Ardelyx is more attractive than BridgeBio Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    BBIO
    BridgeBio Pharma
    9 3 0
  • Is ARDX or BBIO More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.858%.

  • Which is a Better Dividend Stock ARDX or BBIO?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or BBIO?

    Ardelyx quarterly revenues are $116.1M, which are larger than BridgeBio Pharma quarterly revenues of $5.9M. Ardelyx's net income of $4.6M is higher than BridgeBio Pharma's net income of -$265.1M. Notably, Ardelyx's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.75x versus 26.99x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.75x -- $116.1M $4.6M
    BBIO
    BridgeBio Pharma
    26.99x -- $5.9M -$265.1M
  • Which has Higher Returns ARDX or ESPR?

    Esperion Therapeutics has a net margin of 4% compared to Ardelyx's net margin of -30.85%. Ardelyx's return on equity of -24.57% beat Esperion Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    ESPR
    Esperion Therapeutics
    62.91% -$0.11 -$96.4M
  • What do Analysts Say About ARDX or ESPR?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 102.07%. On the other hand Esperion Therapeutics has an analysts' consensus of $6.63 which suggests that it could grow by 319.7%. Given that Esperion Therapeutics has higher upside potential than Ardelyx, analysts believe Esperion Therapeutics is more attractive than Ardelyx.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    ESPR
    Esperion Therapeutics
    3 2 0
  • Is ARDX or ESPR More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison Esperion Therapeutics has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.237%.

  • Which is a Better Dividend Stock ARDX or ESPR?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Esperion Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Esperion Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or ESPR?

    Ardelyx quarterly revenues are $116.1M, which are larger than Esperion Therapeutics quarterly revenues of $69.1M. Ardelyx's net income of $4.6M is higher than Esperion Therapeutics's net income of -$21.3M. Notably, Ardelyx's price-to-earnings ratio is -- while Esperion Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.75x versus 0.91x for Esperion Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.75x -- $116.1M $4.6M
    ESPR
    Esperion Therapeutics
    0.91x -- $69.1M -$21.3M
  • Which has Higher Returns ARDX or INSM?

    Insmed has a net margin of 4% compared to Ardelyx's net margin of -225.53%. Ardelyx's return on equity of -24.57% beat Insmed's return on equity of -41989.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    INSM
    Insmed
    74.96% -$1.32 $1.4B
  • What do Analysts Say About ARDX or INSM?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 102.07%. On the other hand Insmed has an analysts' consensus of $95.54 which suggests that it could grow by 24.1%. Given that Ardelyx has higher upside potential than Insmed, analysts believe Ardelyx is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    INSM
    Insmed
    12 0 0
  • Is ARDX or INSM More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison Insmed has a beta of 1.280, suggesting its more volatile than the S&P 500 by 27.99%.

  • Which is a Better Dividend Stock ARDX or INSM?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or INSM?

    Ardelyx quarterly revenues are $116.1M, which are larger than Insmed quarterly revenues of $104.4M. Ardelyx's net income of $4.6M is higher than Insmed's net income of -$235.5M. Notably, Ardelyx's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.75x versus 34.72x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.75x -- $116.1M $4.6M
    INSM
    Insmed
    34.72x -- $104.4M -$235.5M
  • Which has Higher Returns ARDX or RGEN?

    Repligen has a net margin of 4% compared to Ardelyx's net margin of -20.22%. Ardelyx's return on equity of -24.57% beat Repligen's return on equity of -1.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    RGEN
    Repligen
    23.18% -$0.60 $2.5B
  • What do Analysts Say About ARDX or RGEN?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 102.07%. On the other hand Repligen has an analysts' consensus of $194.07 which suggests that it could grow by 34.45%. Given that Ardelyx has higher upside potential than Repligen, analysts believe Ardelyx is more attractive than Repligen.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    RGEN
    Repligen
    9 6 0
  • Is ARDX or RGEN More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison Repligen has a beta of 0.950, suggesting its less volatile than the S&P 500 by 5.001%.

  • Which is a Better Dividend Stock ARDX or RGEN?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or RGEN?

    Ardelyx quarterly revenues are $116.1M, which are smaller than Repligen quarterly revenues of $167.5M. Ardelyx's net income of $4.6M is higher than Repligen's net income of -$33.9M. Notably, Ardelyx's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.75x versus 12.80x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.75x -- $116.1M $4.6M
    RGEN
    Repligen
    12.80x 633.44x $167.5M -$33.9M
  • Which has Higher Returns ARDX or UTHR?

    United Therapeutics has a net margin of 4% compared to Ardelyx's net margin of 40.94%. Ardelyx's return on equity of -24.57% beat United Therapeutics's return on equity of 20.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
    UTHR
    United Therapeutics
    89.69% $6.19 $6.7B
  • What do Analysts Say About ARDX or UTHR?

    Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 102.07%. On the other hand United Therapeutics has an analysts' consensus of $397.54 which suggests that it could grow by 26.56%. Given that Ardelyx has higher upside potential than United Therapeutics, analysts believe Ardelyx is more attractive than United Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARDX
    Ardelyx
    9 2 0
    UTHR
    United Therapeutics
    7 5 0
  • Is ARDX or UTHR More Risky?

    Ardelyx has a beta of 0.873, which suggesting that the stock is 12.739% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.638, suggesting its less volatile than the S&P 500 by 36.156%.

  • Which is a Better Dividend Stock ARDX or UTHR?

    Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARDX or UTHR?

    Ardelyx quarterly revenues are $116.1M, which are smaller than United Therapeutics quarterly revenues of $735.9M. Ardelyx's net income of $4.6M is lower than United Therapeutics's net income of $301.3M. Notably, Ardelyx's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 12.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.75x versus 5.30x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARDX
    Ardelyx
    3.75x -- $116.1M $4.6M
    UTHR
    United Therapeutics
    5.30x 12.77x $735.9M $301.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Pepsi Vs Coke Stock: Which Is Best?
Pepsi Vs Coke Stock: Which Is Best?

Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
52
RGC alert for Mar 19

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Sell
46
CVNA alert for Mar 19

Carvana [CVNA] is down 10.69% over the past day.

Buy
93
ESLT alert for Mar 19

Elbit Systems [ESLT] is up 10.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock